Jeju, South Korea – The 2025 Hankyung Bio Insight Forum concluded its second day with a resounding consensus: artificial intelligence (AI) is revolutionizing the drug development landscape, and strategic investment in this technology is crucial for economic advancement.

Kim Woo-yeon, a chemistry professor at KAIST, emphasized the transformative potential of AI in drug development, comparing it to the dot-com bubble that propelled South Korea into an IT powerhouse. "The AI revolution presents another opportunity for Korea," Kim stated, urging proactive investment in AI-driven drug development to capitalize on this wave of innovation.

The forum showcased various AI-based drug development approaches, with global pharmaceutical giant Boehringer Ingelheim highlighting its collaborations with IBM and Google to integrate AI into its drug development processes. Kim noted the emergence of bio AI platforms from tech giants like Nvidia, signaling the 본격적인 AI 신약 개발 시대. A McKinsey Global Institute report estimates that generative AI could generate $90 trillion to $160 trillion in economic value for the pharmaceutical industry.

Korean AI drug development companies are demonstrating world-class capabilities. Galaxy, founded by Seoul National University chemistry professor Seok Cha-ok, recently unveiled an AI-discovered antibody drug candidate, a feat yet to be replicated by Google DeepMind's AlphaFold. Kim's own company, Hitz, offers the HyperLab service, which predicts the binding structures of proteins and drugs, boasting comparable performance to AlphaFold3.

Experts predict that AI-driven drugs could emerge within the next few years. To realize this potential, industry leaders stressed the need for investment in data centers with sufficient computing power and the cultivation of prompt engineering talent to maximize AI utilization.

The forum also highlighted advancements in next-generation anticancer therapies, particularly antibody-drug conjugates (ADCs). Companies like Aptis and Intocell shared their progress in developing safe and effective ADC technologies, while Beijing Northland Bio presented promising results from a phase 3 trial of its gene therapy for severe lower limb ischemia.

The 2025 Hankyung Bio Insight Forum underscored the transformative potential of AI in drug development, with industry leaders calling for strategic investment and collaboration to unlock the next generation of life-saving therapies.